<table id="table17" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 17: Response (HIV-1 RNA &lt; 50 copies/mL at Week 96) to PREZISTA/ritonavir 600/100 mg Twice Daily by Baseline Darunavir Phenotype and by Use of Enfuvirtide (ENF): As-treated Analysis of Studies TMC114-C213, TMC114-C202, and TMC114-C215</caption>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<tbody>
<tr>
<th colspan="1"></th>
<th colspan="3">Proportion of Subjects with &lt; 50 copies/mL<br/>at Week 96<br/>N=417</th>
</tr>
<tr>
<th colspan="1">Baseline DRV Phenotype</th>
<th colspan="1">All</th>
<th colspan="1">De Novo ENF</th>
<th colspan="1">Re-Used/<br/>No ENF</th>
</tr>
<tr>
<td>
<content stylecode="bold">Overall</content>
</td>
<td>175/417 (42%)</td>
<td>61/112 (54%)</td>
<td>131/327 (40%)</td>
</tr>
<tr>
<td>
<content stylecode="bold">0 – 7</content>
</td>
<td>148/270 (55%)</td>
<td>44/65 (68%)</td>
<td>104/205 (51%)</td>
</tr>
<tr>
<td>
<content stylecode="bold">&gt; 7 – 20</content>
</td>
<td>16/53 (30%)</td>
<td>7/17 (41%)</td>
<td>9/36 (25%)</td>
</tr>
<tr>
<td>
<content stylecode="bold">&gt; 20</content>
</td>
<td>11/94 (12%)</td>
<td>6/23 (26%)</td>
<td>5/71 (7%)</td>
</tr>
</tbody>
</table>